Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

Open access
Pipe, Steven W., Leebeek, Frank W.G., Recht, Michael, Key, Nigel S., Castaman, Giancarlo, Miesbach, Wolfgang, Lattimore, Susan, Peerlinck, Kathelijne, Van der Valk, Paul, Coppens, Michiel, Kampmann, Peter, Meijer, Karina, O’Connell, Niamh, Pasi, K. John, Hart, Daniel P., Kazmi, Rashid, Astermark, Jan, Hermans, Cedric R.J.R., Klamroth, Robert, Lemons, Richard, Visweshwar, Nathan, von Drygalski, Annette, Young, Guy, Crary, Shelley E., Escobar, Miguel, Gomez, Esteban, Kruse-Jarres, Rebecca, Quon, Doris V., Symington, Emily, Wang, Michael, Wheeler, Allison P., Gut, Robert, Liu, Ying P., Dolmetsch, Ricardo E., Cooper, David L., Li, Yanyan, Goldstein, Brahm, Monahan, Paul E. · 2023 · New England Journal of Medicine

Abstract

BACKGROUND: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity, thereby protecting against bleeding without burdensome factor IX replacement. METHODS: genome copies per kilogram of body weight) to 54 men with hemophilia B (factor IX activity ≤2% of the normal value) regardless of preexisting AAV5 neutralizing antibodies. The primary end point was the annualized bleeding rate, evaluated in a noninferiority analysis comparing the rate during months 7 through 18 after etranacogene dezaparvovec treatment with the rate during the lead-in period. Noninferiority of etranacogene dezaparvovec was defined as an upper limit of the two-sided 95% Wald confidence interval of the annualized bleeding rate ratio that was less than the noninferiority margin of 1.8. Superiority, additional efficacy measures, and safety were also assessed. RESULTS: The annualized bleeding rate decreased from 4.19 (95% confidence interval [CI], 3.22 to 5.45) during the lead-in period to 1.51 (95% CI, 0.81 to 2.82) during months 7 through 18 after treatment, for a rate ratio of 0.36 (95% Wald CI, 0.20 to 0.64; P<0.001), demonstrating noninferiority and superiority of etranacogene dezaparvovec as compared with factor IX prophylaxis. Factor IX activity had increased from baseline by a least-squares mean of 36.2 percentage points (95% CI, 31.4 to 41.0) at 6 months and 34.3 percentage points (95% CI, 29.5 to 39.1) at 18 months after treatment, and usage of factor IX concentrate decreased by a mean of 248,825 IU per year per participant in the post-treatment period (P<0.001 for all three comparisons). Benefits and safety were observed in participants with predose AAV5 neutralizing antibody titers of less than 700. No treatment-related serious adverse events occurred. CONCLUSIONS: Etranacogene dezaparvovec gene therapy was superior to prophylactic factor IX with respect to the annualized bleeding rate, and it had a favorable safety profile. (Funded by uniQure and CSL Behring; HOPE-B ClinicalTrials.gov number, NCT03569891.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2211644

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 364

Metadata

Authors
Pipe, S. W., Leebeek, F. W. G., Recht, M., Key, N. S., Castaman, G., Miesbach, W., Lattimore, S., Peerlinck, K., Van der Valk, P., Coppens, M., Kampmann, P., Meijer, K., O’Connell, N., Pasi, K. J., Hart, D. P., Kazmi, R., Astermark, J., Hermans, C. R. J. R., Klamroth, R., Lemons, R., Visweshwar, N., von Drygalski, A., Young, G., Crary, S. E., Escobar, M., Gomez, E., Kruse-Jarres, R., Quon, D. V., Symington, E., Wang, M., Wheeler, A. P., Gut, R., Liu, Y. P., Dolmetsch, R. E., Cooper, D. L., Li, Y., Goldstein, B., & Monahan, P. E.
Venue
New England Journal of Medicine
Published
2023-02-23
Volume
388
Issue
8
Pages
706-718
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4321480301
Cited by
364
References
33
FWCI
64.86
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. https://app.cochat.ai/papers/10.1056/nejmoa2211644
The paper
Pipe, S. W., Leebeek, F. W. G., Recht, M., Key, N. S., Castaman, G., Miesbach, W., Lattimore, S., Peerlinck, K., Van der Valk, P., Coppens, M., Kampmann, P., Meijer, K., O’Connell, N., Pasi, K. J., Hart, D. P., Kazmi, R., Astermark, J., Hermans, C. R. J. R., Klamroth, R., . . . Monahan, P. E. (2023). Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2211644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.